Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
Questions around mutation T1010I in MET gene: results of next generation sequencing in Polish patient with suspected hereditary adenoid cystic carcinoma.
MET somatic activating mutations are responsible for lymphovenous malformation and can be identified using cell-free DNA next generation sequencing liquid biopsy.
the second family-associating deafness and mutation in the MET gene which strongly supports the hypothesis that the occurrence of pathogenic homozygous mutations in the MET gene causes the appearance of severe to profound deafness
The low incidence of concomitant cMET amplifications at diagnosis suggests that these alterations are acquired in subsequent phases of the disease often during treatment with TKIs.
This is the first study from the Indian subcontinent to identify the frequency of ROS-1 re-arrangements and MET amplification in the Indian lung adenocarcinoma population. c-MET protein expression was identified in 33.33% and ROS-1 protein expression was detected in 3.33% cases.
The present work seeks to assess whether pancreatic carcinomas release exosomes which express c-Met (proto-oncogene mesenchymal-epithelial transition factor) and PD-L1 (programmed cell death 1 ligand 1) and whether the detection of such expression in serum has diagnostic or prognostic meaning for the affected patients.
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
By circumventing an inherent limitation of DNA-based amplicon-mediated testing RNA-based analysis detected a higher proportion of MET exon 14 skipping cases.
MET overexpression was more frequently found in high grade myxofibrosarcoma and the epithelioid variant. Chromosome 7 polysomy rather than MET gene regional amplification might account for the overexpression. of MET protein.
MET exon 14 is a rare mutation in NSCLC and might be associated with a dismal survival. Patients harboring MET exon 14 skipping are eligible for targeted therapy with c-MET inhibitors thus emphasizing the need to screen for this mutation in advanced NSCLCs.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.